{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:40:18Z","timestamp":1785156018608,"version":"3.55.0"},"reference-count":134,"publisher":"Elsevier","isbn-type":[{"value":"9780443192845","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.acc.2022.09.004","type":"book-chapter","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T05:48:40Z","timestamp":1668664120000},"page":"155-204","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers"],"prefix":"10.1016","author":[{"given":"Koji","family":"Kurose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Sakaeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Nakatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Suetsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Irino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Oga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2022.09.004_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.09.004_bb0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0020","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0030","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: a decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/bs.acc.2022.09.004_bb0035","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.21.01589","article-title":"Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer","volume":"40","author":"Chaft","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0040","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0045","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMp2116863","article-title":"The Wild west of checkpoint inhibitor development","volume":"386","author":"Beaver","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0050","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/OP.21.00776","article-title":"Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"18","author":"Schneider","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/bs.acc.2022.09.004_bb0065","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41577-020-0352-z","article-title":"Functional categories of immune inhibitory receptors","volume":"20","author":"Rumpret","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0080","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0085","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1158\/1078-0432.CCR-05-0216","article-title":"XAGE-1 expression in non-small cell lung cancer and antibody response in patients","volume":"11","author":"Nakagawa","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0090","doi-asserted-by":"crossref","first-page":"E649","DOI":"10.1002\/ijc.27359","article-title":"Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients","volume":"131","author":"Ohue","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0095","first-page":"1049","article-title":"Survival of lung adenocarcinoma patients predicted from expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells, Cancer","volume":"4","author":"Ohue","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0100","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jtho.2019.08.008","article-title":"Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-programmed cell death-1 therapy in NSCLC","volume":"14","author":"Ohue","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2021.04.008","article-title":"A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer","volume":"519","author":"Sakai","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2022.09.004_bb0110","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0115","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.09.004_bb0120","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC Expert Panel and Recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"CheckMate-017, -057","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0135","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"CheckMate-026","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0140","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"KEYNOTE-010","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0145","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"KEYNOTE-024","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0150","series-title":"KEYNOTE-042 3-year survival update: 1L pembrolizumab vs chemotherapy for PD-L1-positive locally advanced or metastatic NSCLC","author":"KEYNOTE-042","year":"2021"},{"key":"10.1016\/bs.acc.2022.09.004_bb0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Oak","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0160","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-na\u00efve programmed death-ligand 1-selected NSCLC","volume":"16","author":"IMpower-110","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0170","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0175","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0180","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.09.004_bb0185","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"KEYNOTE-042 3-year survival update: 1L pembrolizumab vs platinum-based chemotherapy for PD-L1+ locally advanced\/metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.09.004_bb0195","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0200","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"KEYNOTE-189","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0205","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"KEYNOTE-407","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomized, open-label, phase 3 trial","volume":"20","author":"IMpower-130","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0215","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"IMpower-131","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0220","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"IMpower-132","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0225","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower 150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"IMpower-150","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0230","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"CheckMate-9LA","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/bs.acc.2022.09.004_bb0235","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in adavanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"CheckMate-227","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0240","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"KEYNOTE-598","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0245","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.acc.2022.09.004_bb0250","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0260","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0270","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.annonc.2022.02.008","article-title":"Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data","volume":"33","author":"P\u00e9rol","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0280","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41577-019-0271-z","article-title":"Immune crosstalk in cancer progression and metastatic spread: a complex conversation","volume":"20","author":"Garner","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The Role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer","volume":"130","author":"Ward","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0290","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2022.09.004_bb0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/bs.acc.2022.09.004_bb0300","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0305","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0310","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0315","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0320","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0325","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","article-title":"Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification","volume":"39","author":"Leader","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0335","first-page":"969","article-title":"Neoepitopes of cancers: looking back, looking ahead, Cancer","volume":"3","author":"Srivastava","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0340","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0345","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI82416","article-title":"Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes","volume":"125","author":"Cohen","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2022.09.004_bb0350","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0355","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0360","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0365","first-page":"146","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade, Cancer","volume":"10","author":"Budimir","year":"2022","journal-title":"Immunol. Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0370","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: A decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0375","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0380","doi-asserted-by":"crossref","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0385","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.immuni.2022.02.006","article-title":"Single-cell immunology: Past, present, and future","volume":"55","author":"Ginhoux","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0390","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0395","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0400","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JTO.0000000000000364","article-title":"Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760)","volume":"10","author":"Kurose","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0410","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2022.09.004_bb0415","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0420","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","article-title":"Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0425","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2022.09.004_bb0430","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0435","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0440","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2022.09.004_bb0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0450","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0455","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic Targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.acc.2022.09.004_bb0460","first-page":"1338","article-title":"Insights into tumor-associated tertiary lymphoid structures: novel targets for antitumor immunity and cancer immunotherapy, Cancer","volume":"8","author":"Rodriguez","year":"2020","journal-title":"Immunol. Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0465","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.abd1329","article-title":"Recruiting T cells in cancer immunotherapy","volume":"372","author":"Yost","year":"2021","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0470","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0475","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0480","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0485","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0490","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/EDBK_320593","article-title":"The Way of the future: personalizing treatment plans through technology","volume":"41","author":"Liefaard","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/bs.acc.2022.09.004_bb0495","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0500","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.20.01572","article-title":"Defining clinical utility of tumor biomarker tests: a clinician's viewpoint","volume":"39","author":"Hayes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0505","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.acc.2022.09.004_bb0510","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \"cancer immunogram\"","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0515","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.004_bb0520","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0525","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0530","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0535","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","article-title":"Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer","volume":"16","author":"Hwang","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0540","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtho.2020.12.026","article-title":"The International association for the study of lung cancer global survey on programmed death-ligand 1 testing for NSCLC","volume":"16","author":"Mino-Kenudson","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0545","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","article-title":"PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee","volume":"15","author":"Lantuejoul","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0550","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acc.2022.09.004_bb0555","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0560","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0565","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0570","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jtho.2021.01.1624","article-title":"The Current lung cancer neoantigen landscape and implications for therapy","volume":"16","author":"Ye","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0575","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.acc.2022.09.004_bb0580","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.acc.2022.09.004_bb0585","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2022.09.004_bb0590","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.427","article-title":"Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC","volume":"14","author":"Garassino","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0595","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0600","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0605","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/bs.acc.2022.09.004_bb0610","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2022.09.004_bb0615","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (CT) antigens: potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/bs.acc.2022.09.004_bb0620","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0625","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86837","article-title":"Profiling cancer testis antigens in non-small-cell lung cancer","volume":"1","author":"Djureinovic","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/bs.acc.2022.09.004_bb0630","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0635","doi-asserted-by":"crossref","first-page":"92966","DOI":"10.18632\/oncotarget.21715","article-title":"Genome-wide identification of cancer\/testis genes and their association with prognosis in a pan-cancer analysis","volume":"8","author":"da Silva","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2022.09.004_bb0640","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jim.2008.10.016","article-title":"Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays","volume":"341","author":"Gnjatic","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/bs.acc.2022.09.004_bb0645","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/bs.acc.2022.09.004_bb0650","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0655","first-page":"4752","article-title":"XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma","volume":"60","author":"Liu","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2022.09.004_bb0660","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/ijc.22583","article-title":"Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients","volume":"120","author":"Kawabata","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2022.09.004_bb0665","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0670","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2013small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2022.09.004_bb0675","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:26:26Z","timestamp":1683087986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192845"],"references-count":134,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.09.004","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}